The royalty rate is 9%. Could be a significant revenue contributor
according to the earning call, Q1: 99M
Anybody has info on Promactus sales in Q1 ?
The Q1 Novartis call may give us some clue whether there is an upside on Promactus IP transition with a much larger oncology sales force
Also the transfer of Promactus to Navartis is complete. Given the larger size of sales force on oncology, there might be an upside
Sentiment: Strong Buy
It seems like that Promacta estimate is higher in the latest presentation as well. With both Promacta and Kryprolis good news, this may explain the recent surge on LGND stock price
Aren't you the one who want to fire management everyday ?